Scp776 is the first therapy to show clinically meaningful efficacy in late-window stroke patients (treated up to 24 hours after onset) – a population with no approved drug options. Scp776 was safe and ...

RESEARCH TRIANGLE, N.C., Oct. 22, 2025 /PRNewswire/ -- Basking Biosciences (Basking), a clinical-stage biopharmaceutical company developing the first reversible thrombolytic therapy for acute ischemic ...

Abstract: With the growing interest in time-interleaved (TI) structures, the conversion rates of ADCs have greatly improved, which has inevitably increased power consumption. Despite the advantages of ...